CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
0.980
+0.080 (8.88%)
Apr 29, 2026, 9:30 AM EDT - Market open
CytoMed Therapeutics Cash Flow Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Net Income | -3.98 | -2.52 | -4.13 | -3.13 | -2.05 | Upgrade
|
| Depreciation & Amortization | 0.4 | 0.33 | 0.38 | 0.39 | 0.33 | Upgrade
|
| Other Amortization | 0 | 0 | - | - | 0 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | -0 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.01 | - | - | 0 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -0.29 | - | - | - | - | Upgrade
|
| Loss (Gain) on Equity Investments | 0.01 | -0.01 | 0.03 | 0.03 | 0.21 | Upgrade
|
| Stock-Based Compensation | 0.69 | - | - | - | - | Upgrade
|
| Other Operating Activities | -0.05 | -0.45 | 0.08 | 1.2 | 0.17 | Upgrade
|
| Change in Accounts Receivable | -0.56 | -0.08 | -0.01 | -0.15 | -0.43 | Upgrade
|
| Change in Accounts Payable | -0 | -0.08 | 0.11 | 0.27 | 0.06 | Upgrade
|
| Change in Unearned Revenue | 0.07 | 0.1 | 0 | -0.01 | - | Upgrade
|
| Operating Cash Flow | -3.7 | -2.71 | -3.53 | -1.4 | -1.71 | Upgrade
|
| Capital Expenditures | -0.64 | -1.4 | -0.06 | -0.47 | -0.58 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 0 | - | Upgrade
|
| Divestitures | 0.7 | 0.16 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.07 | -0.09 | - | - | - | Upgrade
|
| Investment in Securities | 0.77 | 2.5 | -2.77 | - | -0.24 | Upgrade
|
| Other Investing Activities | 0.13 | 0.47 | 0.1 | - | - | Upgrade
|
| Investing Cash Flow | 0.93 | 1.13 | -2.73 | -0.47 | -0.82 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 0.3 | 0.35 | Upgrade
|
| Total Debt Issued | - | - | - | 0.3 | 0.35 | Upgrade
|
| Short-Term Debt Repaid | - | - | -0.3 | -0.35 | - | Upgrade
|
| Long-Term Debt Repaid | -0.05 | -0.04 | -0.04 | -0.08 | -0.06 | Upgrade
|
| Total Debt Repaid | -0.05 | -0.04 | -0.34 | -0.43 | -0.06 | Upgrade
|
| Net Debt Issued (Repaid) | -0.05 | -0.04 | -0.34 | -0.13 | 0.29 | Upgrade
|
| Issuance of Common Stock | 0.28 | - | 11.31 | 1.22 | 4 | Upgrade
|
| Other Financing Activities | -0.02 | -0.02 | -0.05 | -0.13 | -0.12 | Upgrade
|
| Financing Cash Flow | 0.21 | -0.06 | 10.92 | 0.97 | 4.17 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.04 | 0.12 | -0.01 | -0.03 | -0.01 | Upgrade
|
| Net Cash Flow | -2.6 | -1.53 | 4.64 | -0.93 | 1.63 | Upgrade
|
| Free Cash Flow | -4.34 | -4.11 | -3.59 | -1.87 | -2.3 | Upgrade
|
| Free Cash Flow Margin | -503.61% | -816.52% | -706.96% | -514.47% | -2016.27% | Upgrade
|
| Free Cash Flow Per Share | -0.37 | -0.36 | -0.34 | -0.24 | -0.33 | Upgrade
|
| Cash Interest Paid | 0.02 | 0.02 | 0.05 | 0.13 | 0.12 | Upgrade
|
| Cash Income Tax Paid | - | - | 0 | - | - | Upgrade
|
| Levered Free Cash Flow | -2.72 | -3.17 | -2.04 | -1.29 | -1.75 | Upgrade
|
| Unlevered Free Cash Flow | -2.7 | -3.16 | -2.01 | -1.21 | -1.68 | Upgrade
|
| Change in Working Capital | -0.49 | -0.06 | 0.1 | 0.11 | -0.37 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.